A central role for the endothelial NADPH oxidase in atherosclerosis  by Meyer, Jamie W. & Schmitt, Mark E.
Hypothesis
A central role for the endothelial NADPH oxidase in atherosclerosis
Jamie W. Meyera, Mark E. Schmittb;*
aDepartment of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati, 231 Bethesda Avenue, P.O. Box 670524,
Cincinnati, OH 45267-0524, USA
bDepartment of Biochemistry and Molecular Biology, SUNY Upstate Medical University, 750 East Adams Street, Syracuse, NY 13210, USA
Received 10 March 2000
Edited by Barry Halliwell
Abstract An increasing body of evidence has demonstrated that
NADPH oxidase plays a critical role in several early steps
leading toward the development of atherosclerosis. These effects
appear to be carried out by both the ability of O32 to act as a
small second messenger molecule, and potentially the oxidation
of low density lipoprotein by O32 . We describe a model for the
initiation and development of atherosclerosis that suggests
targeted inhibition of NADPH oxidase as a powerful site for
prevention and treatment of this disease.
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1. Introduction
Despite continued research e¡orts, atherosclerosis with its
progression to heart disease, stroke and peripheral vascular
disease continues to be the leading cause of death in all west-
ern civilizations [1]. Leading risk factors for the development
of atherosclerosis include a high serum level of low density
lipoprotein (LDL), smoking, diabetes, obesity, gender, high
blood pressure, increased serum homocysteine and a strong
link to family history suggesting genetic factors as well [2^9].
Various studies have demonstrated that even in advanced
cases of atherosclerosis, the endothelium remains intact and
functional, yet it seems to reside in a state of increased trans-
cytosis, termed hyperpermeable [10,11]. This increased trans-
port across the endothelial cell (EC) layer is responsible for
the continued deposition of LDL into the intima. ECs dem-
onstrate increased rates of transport both in vivo and in vitro
when exposed to atherogenic levels of LDL [12^14]. The in-
creased cellular activity is typi¢ed by massive uptake of LDL,
lipid accumulation in the extracellular matrix of the intima,
oxidation of the accumulating LDL, proliferation of smooth
muscle cells and increased expression of cell adhesion mole-
cules characteristic of an atherosclerotic endothelium.
Atherogenic levels of LDL have also been shown to lead to
a marked increase in NADPH oxidase generated reactive oxy-
gen species (ROS) by the endothelium [15,16]. More signi¢-
cantly, the increase in ROS is both required and su⁄cient to
generate the physiological changes that accompany the gener-
ation of an atherosclerotic endothelium. We describe here a
hypothesis where superoxide (O32 ) generated by an endothelial
NADPH oxidase plays a central role in the development of
atherosclerosis.
2. NADPH oxidase
NADPH oxidase is an inducible electron transport system
found in cells that transfers reducing equivalents from
NADPH to oxygen resulting in O32 generation. This electron
transport system has been primarily studied in neutrophils
[17^20] where it plays an important role in bacterial killing.
The NADPH oxidase consists of a membrane-integrated
b-type cytochrome, cytochrome b558, which is composed of
91 and 22 kDa subunits (gp91phox and p22phox, respec-
tively), and at least three cytosolic proteins (p47phox,
p67phox and p21rac) [21]. NADPH oxidase is a highly regu-
lated enzyme that exists in a dormant unassembled state in
quiescent cells. It is converted to an active assembled form in
response to a stimulus by translocation of cytosolic subunits
(p47phox and p67phox) to the membrane and assembly of
them with the gp91phox and p22phox subunits [21,22].
Recently, the presence of a functional NADPH oxidase in
human ECs has been demonstrated [23]. In addition, compo-
nents of the NADPH oxidase have also been found in the ECs
of other species [24,25]. The endothelial NADPH oxidase ap-
pears to have EC-speci¢c p47phox and p67phox subunits that
remain antigenically related to those expressed in neutrophils.
This suggests that there may be di¡erences in regulation of the
NADPH oxidase between ECs and neutrophils. This is ex-
pected since we postulate that low-level O32 production by
ECs is acting mainly as a second messenger for the regulation
of certain cellular processes. Tissue-speci¢c expression of dif-
ferent NADPH oxidase components may confer di¡erences in
regulation.
Exaggerated generation of O32 from genetically distinct
NADPH oxidase subunits that may assemble and become
active at variable threshold levels may play a role on an in-
dividual basis. An underlying hypothesis is that members of
the general public may have an overactive NADPH oxidase
that accounts for a genetic predisposition to atherosclerosis.
Variants of NADPH oxidase have been reported in cases of
chronic granulomatous disease [26] where neutrophils are un-
able to generate su⁄cient O32 in response to infectious organ-
isms. Indeed, variants with a partially functional NADPH
oxidase may have su⁄cient activity to avoid immunological
problems and may be highly resistant to the atherosclerotic
process.
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3. Superoxide as a second messenger
Several studies have identi¢ed O32 as a second messenger in
a variety of cellular processes [27]. Superoxide has been dem-
onstrated to be involved in the promotion of apoptosis [43],
the constriction of the vascular smooth muscle despite the
presence of nitric oxide (NO) or superoxide dismutase
[28,29], and a number of metabolic changes in EC. Most
notable is an increase in endocytotic activity in the presence
of atherosclerotic levels of LDL [15]. Besides increasing the
level of EC transport, NADPH oxidase-generated O32 is ac-
countable for several other initiating events in the process of
atherosclerosis. It is involved in monocyte attachment to the
EC [30], platelet aggregation [31], the nuclear localization of
the transcription factor nuclear factor kappa B (NF-UB)
[30,32], increased expression of ELAM-1 mRNA in EC [33],
smooth muscle cell proliferation [34], stress ¢ber formation
[35], responsiveness of EC to pulsatile stretch [36], mainte-
nance of vascular tone [37] and oxidation of LDL in macro-
phages [38]. O32 has also been suggested to further activate
NADPH oxidase in a positive feedback mechanism by acting
through phospholipase A2 and the release of arachidonic acid
(AA) (Fig. 1) [39].
4. Activation of NADPH oxidase by LDL
High concentrations of LDL have been shown to lead to
the activation of NADPH oxidase and the subsequent gener-
ation of O32 . Initially, high concentrations of LDL would be
expected to lead to increased binding and uptake by cell sur-
face LDL receptors (Fig. 1). LDL-bound receptor may lead to
the activation of a signal transduction pathway responsible
for the direct activation of NADPH oxidase. This pathway
is expected to be dependent on the activity of phospholipase
A2 and the release of AA, a direct activator of NADPH
oxidase [40] (Fig. 1). Alternatively, LDL degraded in the ly-
sosome might be expected to transiently increase the cytoplas-
mic concentration of AA.
Cytoplasmic free AA, at a threshold level, converts an in-
active NADPH oxidase to its active form. NADPH oxidase
generates increasing amounts of O32 that can promote phos-
pholipase A2 activation and further release of AA [41]. Lib-
erated AA, and its metabolites, markedly escalates NADPH
oxidase cytosolic component (p47phox and p67phox) recruit-
ment and complex assembly generating increased levels of O32 .
This O32 acts as a second messenger molecule to increase the
rate of bulk phase transendothelial transport. This is based on
a coupling of endocytosis to exocytosis, or transcytosis [42].
The increased transcellular transport via bulk phase transcy-
tosis results in increased deposition of LDL on the abluminal
side of the EC (Fig. 1). The exact site of O32 action is currently
unknown, but may be similar to the e¡ect of NO on cGMP
synthase.
5. Oxidation of LDL by NADPH oxidase
The subendothelial accumulation of foam cells is an impor-
tant indicator of the initiation of atherosclerosis. These foam
cells are derived from the unchecked uptake of LDL by
monocytes and macrophages [43,44]. Incubation of LDL
with macrophages does not lead to the production of foam
cells since increased intracellular cholesterol concentrations
lead to down-regulation of the LDL receptor [43]. However,
macrophages and monocytes readily take chemically modi¢ed
or oxidized LDL (ox-LDL) up through a scavenger pathway
that is not down-regulated. Monocytes, macrophages, smooth
Fig. 1. Model for the central involvement of NADPH oxidase in
generation of an atherogenic EC. Atherogenic levels of LDL cause
a release of intracellular AA in a phospholipase A2 dependent man-
ner. The migration of the cytosolic NADPH oxidase subunits
(p47phox and p67phox) to the membrane-bound gp91phox/p22phox
complex is promoted directly by AA and its metabolites. The result
is a production of O32 by the EC-speci¢c NADPH oxidase. Acting
as a second messenger of cellular signaling, the O32 causes a further
increase in phospholipase A2 activity and further release of AA,
and continued activation and assembly of NADPH oxidase in a
positive feedback manner. The increased levels of O32 also cause a
translocation of the transcription factor NF-UB to the nucleus and
the up-regulation of a number of genes associated with the initial
stages of atherosclerosis such as ICAM and ELAM-1. In addition,
O32 causes an increase in the tra⁄cking across the EC layer ac-
counting for the increase in the passage of LDL through the EC.
During transit, the exposure of LDL to high levels of O32 may ac-
count for a generation of ox-LDL (*LDL) on the abluminal side of
the EC. The ox-LDL released from the EC will be taken up by
monocytes/macrophages attracted by the increased number of cell
adhesion molecules, accounting for the production of foam cells
typically observed at the onset of atherosclerosis.
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muscle cells and ECs are all capable of oxidizing LDL in vitro
[36,44,45]. Oxidation of LDL by macrophages has been
shown to be dependent on NADPH oxidase [36] and this
may also be the case in other cell types.
The ¢nding that ECs have their own functionally active
NADPH oxidase raises the possibility that LDL can be oxi-
dized as it traverses the EC layer of the blood vessel. This
modi¢cation would likely occur when LDL crosses the EC
barrier by transcytosis. LDL invaginated into endocytotic
vesicles would be expected to come into contact with O32
generated by the EC NADPH oxidase. Presumably, accessory
factors required for the oxidation of LDL would be present
(i.e. Cu2, etc.). This process would result in ox-LDL being
released to the extracellular matrix on the abluminal side of
the EC. The EC-generated ox-LDL could be the major source
of ox-LDL taken up by foam cells. Thus, the EC plays a
central role in the delivery of LDL to the abluminal side
and potentially in the generation of ox-LDL in the vessel
wall.
6. NADPH oxidase inhibitors
Apocynin, a methoxy-substituted catechol, is a well-charac-
terized inhibitor of NADPH oxidase [46]. It is naturally oc-
curring and has been used by primitive cultures for centuries
in the treatment of in£ammatory diseases. Apocynin has been
shown to be extremely e¡ective at eliminating the increase in
O32 production and increase in transcytosis in ECs associated
with high levels of LDL [23,40]. Since apocynin has been
shown to impede the assembly of the p47phox subunit with
the membrane complex, it likely strikes NADPH oxidase at its
most vulnerable point to limit the production of O32 [46]. This
mechanism was ¢rst described in neutrophils [46], and has
now been demonstrated in ECs as well [23].
It is apparent from other studies that apocynin may have
further anti-atherosclerosis bene¢ts as well. Inhibition of mac-
rophage NADPH oxidase with apocynin reduces cell-medi-
ated oxidation of LDL by up to 89% [38]. Monocyte adhesion
to ECs perturbed by substances that elicit EC ROS produc-
tion results from the induction and cell surface expression of
various adhesion molecules [30]. The mechanism for this re-
sponse likely involves ROS acting as a signal-transducing mol-
ecule in the activation of the transcription factor NF-UB [32].
NADPH oxidase inhibition with apocynin decreases the cell
surface expression of adhesion molecules and signi¢cantly re-
duces monocyte adhesion to the EC surface [30]. Further, the
strategy of using an NADPH oxidase inhibitor has been
shown to be e¡ective at inhibiting ROS generation by ECs
despite an atherogenic level of serum LDL [15]. Perhaps this
direction of atherosclerosis treatment will someday rival the
administration of HMG-CoA reductase inhibitors, since in
rabbits, NADPH oxidase inhibition has been shown to be
e¡ective at suppressing atherogenesis in vivo in spite of highly
elevated serum LDL levels [46].
In addition to apocynin, other vanillins have been shown to
be e¡ective inhibitors of NADPH oxidase including protoca-
techuic, vanillic and ca¡eic acids [47,48]. Indeed, naturally
occurring break down products of various catechols may
have a natural role in controlling NADPH oxidase. Consid-
ered together, the points at which the inhibition of NADPH
oxidase, and the resultant production of O32 , would help curb
this disease are many.
7. Conclusions
At the very least, NADPH oxidase, as it is expressed in the
human endothelium, is a major player in the beginning steps
toward atherosclerosis. The production of ROS by NADPH
oxidase has detrimental e¡ects on the normal physiology of
ECs by causing increased transcytosis of LDL, possible oxi-
dation of LDL in the ECs, and other vascular changes. These
include increased macrophage adhesion and foam cell accu-
mulation initiating the cellular transformation typi¢ed by
fatty streaks and plaque formation. Apocynin has been shown
both in vitro and in vivo to be e¡ective at protecting the
endothelium from the initiating events of atherosclerosis.
The future treatment of this disease should encompass the
use of apocynin, its active form, or another member of the
vanillin family as an agent against NADPH oxidase and its
generation of O32 .
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